BioNTech’s Bold Leap: From COVID Savior to Cancer Crusader Amid Financial Strains
BioNTech is shifting focus from its COVID-19 vaccine success to pioneering mRNA-based cancer treatments, aiming for market presence by 2026. Despite a decline in 2024 financial performance, BioNTech's earnings and…